摘要
目的观察噻托溴胺粉雾剂吸入治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法52例COPD稳定期患者,随机分为噻托溴胺组(T组)和异丙托溴胺组(I组)各26例。2组均采用常规避免吸烟、预防呼吸道感染、祛痰、止咳及按需吸入短效沙丁胺醇气雾剂等治疗。T组在上述综合性治疗的基础上,加用噻托溴胺粉雾剂吸入治疗,I组加用异丙托溴胺气雾剂吸入治疗。测定患者基线肺功能及首次用药后2 h与治疗后2、3、4周的肺功能第1秒用力呼气容积(FEV1)和用力肺活量(FVC)值,观察圣.乔治呼吸评分变化及药物不良反应。结果T组及I组患者首次用药后2 h的FEV1均较用药前升高〔(1 397±205)vs(1 273±187)ml,P<0.01;(1 387±217)vs(1 270±204)ml,P<0.01〕,2组FVC也明显升高〔(2 978±296)vs(2 696±297)ml,P<0.01;(2 939±353)vs(2 668±332)ml,P<0.01〕;用药2、3及4周后T组FEV1较治疗前明显增高〔(1 383±200)、(1 372±194)、(1 368±190)ml vs(1 273±187)ml,P均<0.05〕,FVC也明显增高〔(2 929±319)、(2 880±323)、(2 848±384)ml vs(2 696±297)ml,P均<0.05〕,而I组较治疗前无明显变化。FEV1及FVC较用药前升高值,在首次用药后2 h,T组与I组比较差异无统计学意义(P均>0.05);在用药2、3及4周后,T组均明显高于I组(P均<0.01)。试验结束时,T组圣.乔治呼吸评分有明显改善(P<0.05),I组无改善(P>0.05)。结论规律吸入噻托溴胺4周可显著改善COPD患者的症状和肺功能及圣.乔治呼吸评分。
Objective To evaluate the efficacy and safety of tiotropium in patients with stable chronic obstructive pulmonary disease （COPD）. Methods Fifty-two patients with COPD in stable stage were enrolled in this study. Eligible patients were randomly divided into two groups： tiotropium group （n = 26 ） and ipratropum group （n = 26 ）. On the basis of routine comprehensive treatment , tiotropium aerosol inhalation was added in tiotrepium group, and ipratropum aerosol inhalation was added in ipratropum group. The lung function test was performed at baseline and at 2 hours and 2,3 and 4 weeks after drug administration in two groups. At the same time, the St. Geore＇s respiratory questionnaire score and drug adverse effects were also recorded and evaluated. Results Compared with baseline, the forced expiratory volume in first second （ FEV1 ） at 2 hours after inhalation in tiotropium group and ipratropum group were significantly increased [ （ 1 397 ± 205 ） vs （ 1 273 ± 187） ml, P 〈0. 01 ;（ 1 387 ±217） vs （1 270±204） ml,P 〈0. 01 ],and vital forced capacity （FVC） also increased [（2 978 ±296） vs （2 696 ±297） ml ,P 〈0. 01 ; （2 939 ±353） vs （2 668 ±332） ml ,P 〈 0. 01]. The FEV1 significantly increased at 2,3 and 4 weeks after inhalation in tiotrepium group [ （ 1 383 ± 200）, （ 1 372 ± 194 ）, （ 1 368 ± 190 ） vs （ 1 273 ± 187 ） ml, respectively, all P 〈 0. 05 ], and FVC also increased [（2 929 ± 319 ）, （2 880 ± 323 ）, （2 848 ± 384） vs （2 696 ± 297 ） ml, respectively, all P 〈 0. 05 ], while the differences in ipratropum group had no statistical significance. Compared with ipratropum group, the increased values of FEV1 and FVC at 2 hours after administration were not different in tiotropium group （ all P 〉 0. 05）, but at 2,3 and 4 weeks were higher（ all P 〈 0. 01 ）. At the end of the study, the St. Geore＇s respiratory questionnaire score of patients had improved in tiotropium group,while it not in ipratropum gr
出处
《中国厂矿医学》
2009年第4期395-396,共2页
Chinese Medicine of Factory and Mine
关键词
噻托溴胺
异丙托溴胺
慢性阻塞性肺疾病
肺功能
Tiotropium
Ipratropum
Chronic obstructive pulmonary disease
Lung function
